Kairos Pharma, LTD. - Q1 2025 Filing Summary
Business Context and Reporting Period
Kairos Pharma, LTD. (KAPA) is a clinical-stage biopharmaceutical company focused on developing immunotherapy and cell therapy treatments for oncology. This Form 10-Q covers the quarterly period ended March 31, 2025. The company is classified as a non-accelerated filer, smaller reporting company, and emerging growth company. As of May 13, 2025, there were 16,849,306 shares of common stock outstanding.
Key Financial Metrics
| Metric | Q1 2025 | Q1 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(1,262,000) | $(323,000) |
| Loss Per Share (Basic/Diluted) | $(0.08) | $(0.03) |
| Operating Expenses | $1,266,000 | $287,000 |
| Cash and Cash Equivalents (End of Period) | $3,616,000 | $40,000 |
| Shareholders' Equity | $7,132,000 | $(2,401,000) |
| Accumulated Deficit | $(10,077,000) | $(6,535,000) |
Cash Flow: Net cash used in operating activities was $714,000. Net cash provided by financing activities was $3,058,000, primarily driven by the sale and exercise of pre-funded warrants.
Material Changes vs. Prior Period
- Operating Expenses: Total operating expenses increased significantly from $287,000 in Q1 2024 to $1,266,000 in Q1 2025.
- Research & Development: Rose from $165,000 to $493,000, attributed to the initiation of Phase 2 trials for prostate cancer.
- General & Administrative: Rose from $122,000 to $773,000. Key drivers included a $240,000 increase in vendor advance amortization and a $132,000 increase in stock-related and officer compensation expenses.
- Liquidity Position: Cash balances improved dramatically from $40,000 to $3,616,000 following a private financing in January 2025.
- Capital Structure: The company issued 2,010,000 shares upon the exercise of pre-funded warrants and recorded $484,000 in common stock to be issued for vendor advances and deferred offering costs.
Outlook, Risks, and Management Commentary
- Liquidity and Going Concern: Management expects current cash reserves to fund operations for at least 12 months from the filing date. The company remains dependent on raising additional capital to continue operations and repay liabilities.
- Financing Activities:
- January 2025 PIPE: Closed a private financing for 2,500,000 pre-funded units, receiving net proceeds of approximately $3,145,000.
- Equity Line of Credit (ELOC): An agreement with Helena Global Investment Opportunities for up to $30,000,000 was declared effective on April 24, 2025. Deferred offering costs related to this ELOC totaled $1,705,000 as of March 31, 2025.
- Internal Controls: Management concluded that disclosure controls and procedures were not effective as of March 31, 2025. A material weakness persists regarding the lack of segregation of duties and insufficient review procedures.
- Risks: The company has no approved products and has not generated revenue. Future success depends on clinical trial outcomes, regulatory approvals, and the ability to secure additional funding, which may result in significant dilution.
Investor Verification Checklist
- Cash Runway: Verify the 12-month liquidity estimate against current burn rates and upcoming clinical trial milestones.
- Dilution Impact: Assess the impact of the $30M ELOC and outstanding warrants (4,543,188 shares) on future share count and ownership.
- Vendor Advances: Review the $2,379,000 in vendor advances (net) and the associated service agreements to ensure value is being received for amortized costs.
- Internal Controls: Monitor remediation efforts for the material weakness in internal controls over financial reporting.
- Clinical Progress: Track the status of Phase 1 and Phase 2 trials for ENV 105 (prostate and lung cancer) and KROS 201.